Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|February 9, 2022

INSPIRE and IMvigor011 Trials

Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.

Episodes in this series

EP. 1 Explaining Molecular Residual Disease

EP. 1 Explaining Molecular Residual Disease

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 2 The Evolution of Circulating Tumor DNA in Oncology

EP. 3 MRD Assessments

EP. 3 MRD Assessments

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 4 MRD Results and Guiding Treatment Decisions

EP. 5 MRD and Value-Based Care Models

EP. 5 MRD and Value-Based Care Models

EP. 6 Supporting MRD Availability

EP. 6 Supporting MRD Availability

EP. 7 INSPIRE and IMvigor011 Trials

EP. 7 INSPIRE and IMvigor011 Trials

EP. 8 Potential Changes for MRD in the Future

EP. 8 Potential Changes for MRD in the Future

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

Social Factors Shape Diabetes, Dementia Risk Across Populations

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD